Moneycontrol
HomeNewsBusinessEconomySugar output falls 20% in October-April; last 2 months sales dip by 10 lakh tonne due to lockdown

Sugar output falls 20% in October-April; last 2 months sales dip by 10 lakh tonne due to lockdown

Sugar sales in March and April declined by 10 lakh tonne because of the imposition of nationwide lockdown to control the coronavirus disease, the Indian Sugar Mills Association (ISMA) said.

May 01, 2020 / 17:48 IST
Story continues below Advertisement

India's sugar production fell 20 per cent to 258.01 lakh tonne in the current marketing year ending September due to lower cane output, while sales plummeted during the last two months because of the lockdown, an industry body said. Production stood at 321.71 lakh tonne in the corresponding period (October-April) of 2018-19 marketing year.

Sugar sales in March and April declined by 10 lakh tonne because of the imposition of nationwide lockdown to control the coronavirus disease, the Indian Sugar Mills Association (ISMA) said.

Story continues below Advertisement

"Sugar mills across the country have produced 258.01 lakh tonne of sugar between October 1, 2019 and  April 30, 2020. This is about 63.70 lakh tonne less than 321.71 lakh tonne produced at the same time last year," ISMA said in a statement.

At present, 90 sugar mills are operating.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show